Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or
hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate
hepatic impairement or severe hepatic impairment) as defined by the National Cancer Institute
(NCI) Organ Dysfunction Working Group.